Navigation

TA206 Lymphoma (non-Hodgkin's) - bendamustine (terminated appraisal): advice

The published full guidance on bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab.

It presents NICE's advice to the NHS on the use of this treatment.

This page was last updated: 22 October 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.